Angeline L. Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angeline L. Wang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Alshaikhsalama
Department of Ophthalmology, UT Southwestern Medical Center, Dallas, Texas; and
3 shared publications Ahmed M. Alshaikhsalama
Department of Ophthalmology, UT Southwestern Medical Center, Dallas, USA
3 shared publicationsYu-Guang He
Department of Ophthalmology, UT Southwestern Medical Center, Dallas, Texas; Children's Medical Center Dallas, Dallas, Texas
3 shared publications- Alice Yang Zhang
Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
2 shared publications - Bita Momenaei
The Retina Service of Wills Eye Hospital, Wills Eye Physicians-Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, PA, USA
2 shared publications Cody Hansen
2 shared publications
Latest Publications
- 26 September 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 292, 779-789
Organism-Specific Clinical Features and Outcomes of Culture-Positive Endogenous Endophthalmitis: A Multicenter Cohort Study Over 12 Years
- 26 September 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 292, 779-789
Organism-Specific Clinical Features and Outcomes of Culture-Positive Endogenous Endophthalmitis: A Multicenter Cohort Study Over 12 Years
- Open Access
- 5 August 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-13
Gout and diabetic retinopathy: elevated risks and the protective role of urate-lowering therapy
- 5 August 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-13
Open AccessGout and diabetic retinopathy: elevated risks and the protective role of urate-lowering therapy
- 23 May 2026
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 30 (3) , 104863
Ocular findings and long-term outcomes in pediatric abusive head trauma
- 23 May 2026
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 30 (3) , 104863
Ocular findings and long-term outcomes in pediatric abusive head trauma
- Open Access
- 8 April 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (5) , 1081-1087
Acute Retinal Necrosis in an Infant With Corneal and Macular Scarring
Purpose: To report a rare case of neonatal acute retinal necrosis (ARN) caused by herpes simplex virus type 2 (HSV-2), highlighting its clinical features, diagnostic challenges, and management outcomes. Methods: A single case was reviewed. Results: ARN is a rare and rapidly progressive ocular condition caused by intraocular herpesvirus infections, including HSV and varicella-zoster virus (VZV). ARN is uncommon in neonates, with few cases documented in the literature. Its nonspecific signs and symptoms, such as redness, eye pain, and decreased vision, combined with the absence of established diagnostic and treatment guidelines, make its recognition in this age group challenging. We report a case of a 33-day-old infant diagnosed with HSV-2–associated ARN, incidentally identified during retinopathy of prematurity screening. The diagnosis was confirmed through characteristic clinical findings and positive serum HSV-2 testing. Prompt antiviral treatment yielded favorable clinical outcomes. Notably, this case demonstrated bilateral macular scars and corneal scarring, both rarely reported in neonatal ARN. Conclusions: This case, along with a review of the literature, expands the understanding of ARN in neonates and underscores the importance of early recognition and timely antiviral therapy to optimize visual outcomes.
- 8 April 2026
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 10 (5) , 1081-1087
Open AccessAcute Retinal Necrosis in an Infant With Corneal and Macular Scarring
Purpose: To report a rare case of neonatal acute retinal necrosis (ARN) caused by herpes simplex virus type 2 (HSV-2), highlighting its clinical features, diagnostic challenges, and management outcomes. Methods: A single case was reviewed. Results: ARN is a rare and rapidly progressive ocular condition caused by intraocular herpesvirus infections, including HSV and varicella-zoster virus (VZV). ARN is uncommon in neonates, with few cases documented in the literature. Its nonspecific signs and symptoms, such as redness, eye pain, and decreased vision, combined with the absence of established diagnostic and treatment guidelines, make its recognition in this age group challenging. We report a case of a 33-day-old infant diagnosed with HSV-2–associated ARN, incidentally identified during retinopathy of prematurity screening. The diagnosis was confirmed through characteristic clinical findings and positive serum HSV-2 testing. Prompt antiviral treatment yielded favorable clinical outcomes. Notably, this case demonstrated bilateral macular scars and corneal scarring, both rarely reported in neonatal ARN. Conclusions: This case, along with a review of the literature, expands the understanding of ARN in neonates and underscores the importance of early recognition and timely antiviral therapy to optimize visual outcomes.
- Open Access
- 11 December 2025
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (3) , 745-754
Investigating ocular ischemic events following pars plana vitrectomy
Objective: To assess the incidence of post–vitrectomy ocular ischemic events, including retinal artery occlusion (RAO), retinal vein occlusion (RVO), and non-arteritic ischemic optic neuropathy (NAION). Methods: This retrospective cohort study examined 120,350 patients who underwent vitrectomy. Using a multicenter healthcare database, patients with a CPT code for any vitrectomy procedure were assessed for subsequent ocular ischemic events. A follow-up analysis of 510,915 patients was performed to determine the risk attributable to vitrectomy versus clinical characteristics. Exclusion criteria included history of prior ocular ischemic events and less than 6 months of follow up. Results: The first post-operative month had a significantly higher risk of vascular occlusions compared to the 6–12-month period, with incidence rate ratios (IRRs) of 9.69 (95% CI: 6.9–13.7) for RAO, 11.43 (95% CI: 9.3–14.1) for RVO, and 8.75 (95% CI: 5.2–14.7) for NAION. The IRR for overall ischemic events was also increased during the first month following vitrectomy at 10.7 (95% CI: 9.0–12.7) and remained elevated up to 6 months later with an IRR of 1.49 (95% CI: 1.2–1.8) for the 3–6-month period compared to 6–12-months postoperatively. A separate multivariate analysis revealed that the risk of overall ischemic events was most correlated to vitrectomy (hazard ratio [HR] 3.32, 95% CI: 3.10–3.57) over multiple variables including cataract surgery (HR 1.49, 95% CI: 1.42–1.56) and nicotine use (HR 1.15, 95% CI: 1.08–1.22). Conclusions: Vitrectomy is correlated with significantly increased risk of ocular ischemic events, particularly within the first month following surgery. This risk gradually declines but remains elevated up to 6 months postoperatively.
- 11 December 2025
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 36 (3) , 745-754
Open AccessInvestigating ocular ischemic events following pars plana vitrectomy
Objective: To assess the incidence of post–vitrectomy ocular ischemic events, including retinal artery occlusion (RAO), retinal vein occlusion (RVO), and non-arteritic ischemic optic neuropathy (NAION). Methods: This retrospective cohort study examined 120,350 patients who underwent vitrectomy. Using a multicenter healthcare database, patients with a CPT code for any vitrectomy procedure were assessed for subsequent ocular ischemic events. A follow-up analysis of 510,915 patients was performed to determine the risk attributable to vitrectomy versus clinical characteristics. Exclusion criteria included history of prior ocular ischemic events and less than 6 months of follow up. Results: The first post-operative month had a significantly higher risk of vascular occlusions compared to the 6–12-month period, with incidence rate ratios (IRRs) of 9.69 (95% CI: 6.9–13.7) for RAO, 11.43 (95% CI: 9.3–14.1) for RVO, and 8.75 (95% CI: 5.2–14.7) for NAION. The IRR for overall ischemic events was also increased during the first month following vitrectomy at 10.7 (95% CI: 9.0–12.7) and remained elevated up to 6 months later with an IRR of 1.49 (95% CI: 1.2–1.8) for the 3–6-month period compared to 6–12-months postoperatively. A separate multivariate analysis revealed that the risk of overall ischemic events was most correlated to vitrectomy (hazard ratio [HR] 3.32, 95% CI: 3.10–3.57) over multiple variables including cataract surgery (HR 1.49, 95% CI: 1.42–1.56) and nicotine use (HR 1.15, 95% CI: 1.08–1.22). Conclusions: Vitrectomy is correlated with significantly increased risk of ocular ischemic events, particularly within the first month following surgery. This risk gradually declines but remains elevated up to 6 months postoperatively.
- 22 July 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (1) , 61-70
Visual Outcomes in Cases of Endogenous Endophthalmitis
- 22 July 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (1) , 61-70
Visual Outcomes in Cases of Endogenous Endophthalmitis
- Open Access
- 22 April 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-7
Racial disparities in patients with proliferative diabetic retinopathy treated with pars plana vitrectomy in an underserved population
Proliferative diabetic retinopathy (PDR) is a serious microvascular complication of diabetes that can lead to irreversible vision loss. Prior research studies have documented how racial minorities with PDR experience less routine screening, less frequent treatment, and more complications. Although pars plana vitrectomy (PPV) is a widely used treatment modality for PDR, minimal research is currently available addressing how race impacts surgical presentation and outcomes. This study is a retrospective case series involving a sample of patients who underwent PPV for PDR at a county hospital between January 1, 2014, and December 30, 2019. Patients were included if they had a follow-up period of at least six months. The data collection included demographic data, medical history, surgical indications, operative outcomes, and complications. Snellen best corrected visual acuity (BCVA) was converted to logMAR for data analysis. Statistical analysis included chi-square testing, analysis of variance, generalized linear modeling, and multivariate analysis. The study cohort consisted of 715 patients (915 eyes) receiving PPV for the treatment of PDR. In the patient cohort, 576 patients were Hispanic (80.6%), 103 patients were Black (14.4%), and 36 patients were Non-Hispanic White (5.0%). The majority of the patient cohort (75%) received charity insurance. Black patients had significantly higher pre-operative HbA1c levels than Hispanic patients (8.779 vs. 8.271, p = 0.011). Black patients were more likely to undergo surgery for a TRD than Hispanic patients (OR: 0.901, p < 0.001) and White patients (OR: 0.870, p < 0.001) and were more likely to have macula-involving TRDs compared to Hispanic patients (OR: 1.194, p < 0.001) and White patients (OR: 1.289, p = 0.005). Based on the multivariate analysis performed, race did not impact surgical outcomes, including post-operative visual acuity, anatomic success rate, and the need for a repeat surgery. The main findings of this study indicate that Black patients are receiving surgery when they have more advanced diabetic retinopathy. However, there were no significant differences in surgical outcomes.
- 22 April 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-7
Open AccessRacial disparities in patients with proliferative diabetic retinopathy treated with pars plana vitrectomy in an underserved population
Proliferative diabetic retinopathy (PDR) is a serious microvascular complication of diabetes that can lead to irreversible vision loss. Prior research studies have documented how racial minorities with PDR experience less routine screening, less frequent treatment, and more complications. Although pars plana vitrectomy (PPV) is a widely used treatment modality for PDR, minimal research is currently available addressing how race impacts surgical presentation and outcomes. This study is a retrospective case series involving a sample of patients who underwent PPV for PDR at a county hospital between January 1, 2014, and December 30, 2019. Patients were included if they had a follow-up period of at least six months. The data collection included demographic data, medical history, surgical indications, operative outcomes, and complications. Snellen best corrected visual acuity (BCVA) was converted to logMAR for data analysis. Statistical analysis included chi-square testing, analysis of variance, generalized linear modeling, and multivariate analysis. The study cohort consisted of 715 patients (915 eyes) receiving PPV for the treatment of PDR. In the patient cohort, 576 patients were Hispanic (80.6%), 103 patients were Black (14.4%), and 36 patients were Non-Hispanic White (5.0%). The majority of the patient cohort (75%) received charity insurance. Black patients had significantly higher pre-operative HbA1c levels than Hispanic patients (8.779 vs. 8.271, p = 0.011). Black patients were more likely to undergo surgery for a TRD than Hispanic patients (OR: 0.901, p < 0.001) and White patients (OR: 0.870, p < 0.001) and were more likely to have macula-involving TRDs compared to Hispanic patients (OR: 1.194, p < 0.001) and White patients (OR: 1.289, p = 0.005). Based on the multivariate analysis performed, race did not impact surgical outcomes, including post-operative visual acuity, anatomic success rate, and the need for a repeat surgery. The main findings of this study indicate that Black patients are receiving surgery when they have more advanced diabetic retinopathy. However, there were no significant differences in surgical outcomes.
- 21 November 2024
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (6) , 564-569
Outcomes and Need for Additional Interventions after Intravitreal Bevacizumab for Retinopathy of Prematurity
- 21 November 2024
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (6) , 564-569
Outcomes and Need for Additional Interventions after Intravitreal Bevacizumab for Retinopathy of Prematurity
- 4 March 2024
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (8) , 823-831
Clinical Characteristics and Surgical Outcomes of Patients Undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
- 4 March 2024
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (8) , 823-831
Clinical Characteristics and Surgical Outcomes of Patients Undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy